Floatz logo

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE

Dry Eye Syndromes

Seema CapoorSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Dry Eye Syndromes cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Barbara Burgos Blasco
Phase 4BBB
Insulin Human
Khyber Teaching Hospital
Phase 4BB
Sodium Hyaluronate
Peking University Third Hospital
Phase 4BB
Azithromycin
University of California, San Francisco
Phase 4BB
VITAMIN D
University of Faisalabad
Phase 3BB

View all 10 →

Same molecule, other indications

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE is also rated in:

Low Back PainDormant
BBB
Indicative ·
74 / 100
View asset →
PainDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic OsteoarthritisDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →